In 2007, Marcia Angell, former editor of the New England Journal of Medicine and associate professor of social medicine at Harvard Medical School, told Stern, a German-language weekly, that AstraZeneca scientists had misrepresented their research into the drug`s efficacy: “Instead of presumably using comparable doses [of each drug], the company`s scientists used Nexium in higher doses. They compared 20 and 40 mg of Nexium with 20 mg of Prilosec. Our people are our greatest asset and we know what is possible when we assemble a talented and diverse team that believes in what science can do. DISC, along with our other strategic science centres around the world, demonstrate our focus on innovative science while ensuring our company is a great place to work. Our five core values guide how we work and the behaviours that underpin our efforts to succeed. For example, we are committed to tracking where science takes us and considering patients in our most important decisions. On May 19, 2014, AstraZeneca rejected a “final offer” from Pfizer of £55 per share, valuing the company at £69.4 billion ($117 billion). The companies have been meeting since January 2014. Had the acquisition progressed, Pfizer would have become the world`s largest drug manufacturer. The transaction would also have been the largest foreign acquisition of a British company. Many in Britain, including politicians and academics, had spoken out against the deal.  In July 2014, the company entered into an agreement with Almirall to acquire its subsidiary Almirall Sofotec and its lung treatments, including the COPD drug Eklira.
The $2.1 billion deal included a $1.2 billion allocation for the development of AstraZeneca`s ventilator business, one of AstraZeneca`s three therapeutic target areas announced last year. In August 2014, the company announced that it had entered into a three-year collaboration with Mitsubishi Tanabe Pharma in the field of diabetic kidney disease.  In September 2014, the Company co-developed its BACE inhibitor candidate AZD3292 with Eli Lilly for the treatment of Alzheimer`s disease. The deal could bring the company up to $500 million.  In November 2014, MedImmune, the company`s biologics research and development business, agreed to acquire Definiens for over $150 million. The Company has also initiated a Phase I/II collaboration with Pharmacyclics and Janssen Biotech to evaluate combination therapies.  Also in November of the same year, the Company agreed to sell its lipodystrophy treatment business to Aegerion Pharmaceuticals for over $325 million.  In December, the company received accelerated FDA approval for olaparib for the treatment of women with advanced ovarian cancer with a BRCA gene mutation. On average, a key endpoint for drug approval was the ability to shrink tumors in patients for 7.9 months.  The Gaithersburg, MD campus is one of three global research and development centers dedicated to improving pipeline productivity and establishing the company as a global leader in biopharmaceutical innovation, along with Cambridge, UK and Gothenburg, Sweden. In mid-March, the company announced that it would market naloxegol with Daiichi Sankyo in a deal worth up to $825 million.
 In late April, the company announced a series of collaborations valued at $1.8 billion; First, the development and commercialization of MEDI4736 with Celgene for the treatment of non-Hodgkin lymphoma, myelodysplastic syndromes and multiple myeloma, with AstraZeneca receiving $450 million. The second of two agreements is an agreement for a combination treatment of MEDI4736 and Innate Pharma`s Phase II anti-NKG2A antibody IPH2201 for up to $1.275 billion. INO-3112 targets human papillomavirus types 16 and 18.  In September, Valeant licensed Brodalumab to the company for up to $445 million.   On November 6, it was reported that AstraZeneca had acquired ZS Pharma for $2.7 billion.  In December, the company announced its intention to acquire Takeda Pharmaceutical`s respiratory portfolio, namely Alvesco and Omnaris for $575 million.  A day later, the company announced that it had acquired a 55% majority stake in Acerta for $4 billion. As part of the transaction, the Company will receive commercial rights to Acera`s irreversible oral tyrosine kinase inhibitor, acalabrutinib (ACP-196), which is currently in Phase III development for B-cell blood cancer and in Phase I or II clinical trials in solid tumors.  In 2015, it was the eighth largest pharmaceutical company in the world by revenue.
 Determine AstraZeneca Plc`s go-to-market offering and better understand the company`s clinical operations, recruitment and study strategy.